VolitionRx Limited (NYSE American: VNRX) has announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company says is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (ctDNA). This development addresses a longstanding challenge in liquid biopsy: separating cancer-derived DNA from the overwhelming background of healthy cell-free DNA. By creating highly enriched tumor DNA datasets, the technology could significantly improve cancer detection and monitoring.
The published research describes a two-step process combining physical sample enrichment with bioinformatic filtering to produce sequencing datasets with greater than 99% purity. Early validation studies reported strong cancer detection results, including no false positives in initial cohorts and high detection rates for early-stage cancers. Additional blinded studies have produced encouraging findings, according to the company.
Volition is now advancing larger validation studies, working with oncology key opinion leaders, and expanding patent protection for the technology as it explores commercialization opportunities. The company is conducting technical evaluations with potential licensing partners and estimates that the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications, totaling a potential $36 billion market.
The implications of this announcement are significant. Liquid biopsy is a rapidly growing field, but the challenge of isolating pure ctDNA has limited its sensitivity and specificity. If Capture-Seq delivers on its promise of high-purity ctDNA, it could enable earlier detection of cancers, when treatment is most effective, and improve monitoring of minimal residual disease, potentially transforming patient outcomes. The peer-reviewed publication adds credibility to the technology and may accelerate adoption.
Volition is a multinational company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
For more information, visit the company's website at https://volition.com/. To view the full press release, visit https://ibn.fm/nuJEs.
